Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 1/20 | 0.53 |
| ▸ | APP | P05067 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.50 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.50 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7934862 | 0.90 | MAPT (0.55) | APPTSHRADRB2ADRB1ADRB3 | |
| SCHEMBL6228324 | 0.89 | AR (0.61) | ARTSHRMAPK1MAPTLMNA | |
| SCHEMBL11566950 | 0.84 | MAPT (0.50) | APPTSHRADRB2ADRB1ADRB3 | |
| SCHEMBL5010945 | 0.83 | AR (0.56) | ARTSHRMAPK1MAPTLMNA | |
| SCHEMBL8811629 | 0.83 | AR (0.56) | ARTSHRMAPK1MAPTLMNA | |
| SCHEMBL6049252 | 0.82 | TDP1 (0.55) | APPTSHRMAPK1ADRB2ADRB1 | |
| SCHEMBL9002377 | 0.82 | AR (0.55) | ARAPPTSHRADRB2ADRB1 | |
| SCHEMBL20314692 | 0.82 | AR (0.54) | ARTSHRMAPK1MAPTLMNA | |
| SCHEMBL11247517 | 0.82 | PTGS1 (0.59) | ARTSHRMAPK1ADRB2ADRB1 | |
| SCHEMBL43535 | 0.82 | PTGS1 (0.59) | ARTSHRMAPK1ADRB2ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 117 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11007193-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2021-05-18 | — | — | US | disclosed |
| US-10828301-B2 | 2,4-pyrimidinediamine compounds and their uses | Rigel Pharmceuticals, Inc. (US) | 2020-11-10 | — | — | US | disclosed |
| US-10752624-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2020-08-25 | — | — | US | disclosed |
| US-10709703-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2020-07-14 | — | — | US | disclosed |
| US-10682350-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2020-06-16 | — | — | US | disclosed |
| US-20200085820-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2020-03-19 | — | — | US | disclosed |
| US-20190255047-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2019-08-22 | — | — | US | disclosed |
| US-10369148-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2019-08-06 | — | — | US | disclosed |
| US-10314840-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2019-06-11 | — | — | US | disclosed |
| US-20180305356-A1 | NOVEL KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2018-10-25 | — | — | US | disclosed |
| US-5464781-A | TREATING RHEUMATIC DISEASES | THE BOOTS COMPANY PLC (GB) | 1995-11-07 | — | — | US | disclosed |
| US-5395910-A | Photostable polymers | AKZO NOBEL N.V. (NL) | 1995-03-07 | — | — | US | disclosed |
| WO-1995000511-A1 | CONDENSED 4-AMINOPYRIDINES WITH ANTIRHEUMATIC ACTIVITY | KNOLL AG (DE) | 1995-01-05 | — | — | WO | disclosed |
| EP-0618916-A1 | ANTI-RHEUMATIC NAPHTHYRIDINE DERIVATIVES | Knoll AG (DE) | 1994-10-12 | — | — | EP | disclosed |
| WO-1993013097-A1 | ANTI-RHEUMATIC NAPHTHYRIDINE DERIVATIVES | THE BOOTS COMPANY PLC (GB) | 1993-07-08 | — | — | WO | disclosed |
| EP-0550105-A2 | Liquid-crystalline polyurethanes, compositions of said liquid-crystalline polyurethanes, and a device for optical data storage comprising a liquid-crystalline polyurethane | Akzo Nobel N.V. (NL) | 1993-07-07 | — | — | EP | disclosed |
| EP-0178073-B1 | AMIDE COMPOUNDS, PROCESS FOR PREPARING THE SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | TAIHO PHARMACEUTICAL COMPANY, LIMITED (JP) | 1988-04-27 | — | — | EP | disclosed |
| US-4670583-A | ANTIALLERGENS | TAIHO PHARMACEUTICAL COMPANY, LIMITED (JP) | 1987-06-02 | — | — | US | disclosed |
| EP-0178073-A1 | amide compounds, process for preparing the same and pharmaceutical compositions containing the same | TAIHO PHARMACEUTICAL COMPANY, LIMITED (JP) | 1986-04-16 | — | — | EP | disclosed |
| US-4104284-A | Nitroanthraquinones | BAYER AKTIENGESELLSCHAFT (DE) | 1978-08-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180305356-A1 | NOVEL KINASE INHIBITORS | LRRK2, MYLK2, MYLK | AR 1705/4885APP 917/4885TSHR 1137/4885 |
| US-20200085820-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | FCER2, FCGR1A, FCGR2A | AR 3991/4885APP 1782/4885TSHR 1524/4885 |
| US-10682350-B2 | 2,4-pyrimidinediamine compounds and their uses | FCER2, FCGR1A, FCGR2A | AR 3991/4885APP 1782/4885TSHR 1524/4885 |
| US-10709703-B2 | 2,4-pyrimidinediamine compounds and their uses | FCER2, FCGR1A, FCGR2A | AR 3991/4885APP 1782/4885TSHR 1524/4885 |
| US-10314840-B2 | 2,4-pyrimidinediamine compounds and their uses | FCER2, FCGR1A, FCGR2A | AR 3991/4885APP 1782/4885TSHR 1524/4885 |
| US-10369148-B2 | 2,4-pyrimidinediamine compounds and their uses | FCER2, FCGR1A, FCGR2A | AR 3991/4885APP 1782/4885TSHR 1524/4885 |
| US-11007193-B2 | 2,4-pyrimidinediamine compounds and their uses | FCER2, FCGR1A, FCGR2A | AR 3991/4885APP 1782/4885TSHR 1524/4885 |
| US-20190255047-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | FCER2, FCGR1A, FCGR2A | AR 3991/4885APP 1782/4885TSHR 1524/4885 |
| US-10828301-B2 | 2,4-pyrimidinediamine compounds and their uses | FCER2, FCGR1A, FCGR2A | AR 3991/4885APP 1782/4885TSHR 1524/4885 |
| US-10752624-B2 | Kinase inhibitors | LRRK2, MYLK2, MYLK | AR 1845/4885APP 850/4885TSHR 1024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.